Product Information
TRELEGY ELLIPTA 100-62.5-25 is a brand product labeled by GlaxoSmithKline LLC, priced at $11.1524 per EA under NDC 00173088710. Its NADAC has been published 444 times since Feb 21, 2018.
FDA first approved this application on Sep 18, 2017.
TRELEGY ELLIPTA 100-62.5-25
fluticasone furoate, umeclidinium bromide and vilanterol trifenatateStrength
100; 62.5; 25 ug/1; ug/1; ug/1
Manufacturer
GlaxoSmithKline LLCNDC
00173088710
Classification
Brand
Dosage Form
POWDER
Route
RESPIRATORY (INHALATION)
Effective Date
8/19/2026
Active Ingredients
FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATEApproval Type
New Drug (NDA)
FDA Application
NDA209482FDA Approved
9/18/2017
On Market Since
9/18/2017
Pharmacological Classes
Price Statistics
The NADAC for TRELEGY ELLIPTA 100-62.5-25 has been published 444 times since Feb 21, 2018, and over the history we have for it it has risen 31.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $11.1524 per EA |
|---|---|
| All-time high | $11.1629 (May 13, 2026) |
| All-time low | $8.4881 (Dec 19, 2018) |
| 52-week high | $11.1629 |
| 52-week low | $10.8338 |
| Median price | $9.9314 |
| Average price | $9.8195 |
| Largest weekly change | +5.0% (Jan 8, 2020) |
| Weeks tracked | 444 |
| Tracking since | Feb 21, 2018 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 1% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of TRELEGY ELLIPTA 100-62.5-25?
The current National Average Drug Acquisition Cost (NADAC) for TRELEGY ELLIPTA 100-62.5-25, manufactured by GlaxoSmithKline LLC, is $11.1524 per EA (NDC 00173088710), effective Aug 19, 2026.
How has the price of TRELEGY ELLIPTA 100-62.5-25 changed over time?
Over the history we have for it, the NADAC for TRELEGY ELLIPTA 100-62.5-25 has risen 31.4%. It has been tracked across 444 weekly CMS publications since Feb 21, 2018.
What are the highest and lowest recorded NADAC prices for TRELEGY ELLIPTA 100-62.5-25?
Since Feb 21, 2018, the NADAC for TRELEGY ELLIPTA 100-62.5-25 has ranged from a low of $8.4881 (Dec 19, 2018) to a high of $11.1629 (May 13, 2026), with a median of $9.9314 per EA.
Are there cheaper alternatives to TRELEGY ELLIPTA 100-62.5-25?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TRELEGY ELLIPTA 100-62.5-25, is $11.0919 per EA — about 1% below TRELEGY ELLIPTA 100-62.5-25.
Who manufactures TRELEGY ELLIPTA 100-62.5-25?
TRELEGY ELLIPTA 100-62.5-25 (NDC 00173088710) is labeled by GlaxoSmithKline LLC, and CMS classifies it as a brand product.